コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nicity, disease duration, and treatment with immunosuppressive agents).
2 ycophenolic acid (MPA), is widely used as an immunosuppressive agent.
3 ecause FTY720 is generally regarded as a new immunosuppressive agent.
4 e to rapamycin (RAPA), a "tolerance-sparing" immunosuppressive agent.
5 sage to >40 mg/day and/or the addition of an immunosuppressive agent.
6 its and to have filled a prescription for an immunosuppressive agent.
7 many studies currently are ongoing with this immunosuppressive agent.
8 ids, appears to be the single most effective immunosuppressive agent.
9 h-dose corticosteroids plus a broad-spectrum immunosuppressive agent.
10 ssive activity and could be beneficial as an immunosuppressive agent.
11 ces the total cumulative dose of this potent immunosuppressive agent.
12 Thus WY14,643, a fibrate, is a profound immunosuppressive agent.
13 tabolite of leflunomide, a recently approved immunosuppressive agent.
14 in combination with the use of conventional immunosuppressive agent.
15 systemic corticosteroids with or without an immunosuppressive agent.
16 l or for the design of an original series of immunosuppressive agent.
17 rovided new targets for developing potential immunosuppressive agents.
18 ns and further evaluation of action-specific immunosuppressive agents.
19 iviral therapy and reduced administration of immunosuppressive agents.
20 y T cells, and targets of current and future immunosuppressive agents.
21 ulation and are suppressed by currently used immunosuppressive agents.
22 ssary and potentially harmful treatment with immunosuppressive agents.
23 such as ruxolitinib, have been developed as immunosuppressive agents.
24 m antimalarial agents to corticosteroids and immunosuppressive agents.
25 uggest that they may have potential as novel immunosuppressive agents.
26 ia) in 528 kidney recipients using different immunosuppressive agents.
27 salicylate and corticosteroids, and on novel immunosuppressive agents.
28 -phosphate (S1P) receptor agonists are novel immunosuppressive agents.
29 closely linked with the development of newer immunosuppressive agents.
30 dequately to a number of currently available immunosuppressive agents.
31 ly recognized, and treated with conventional immunosuppressive agents.
32 plantation (LTx), including the influence of immunosuppressive agents.
33 tary approach to conventional treatment with immunosuppressive agents.
34 ation with traditional anti-inflammatory and immunosuppressive agents.
35 hniques and the development of more powerful immunosuppressive agents.
36 litis is managed with corticosteroids and/or immunosuppressive agents.
37 ed, however, that these disorders respond to immunosuppressive agents.
38 n (mTOR) such as rapamycin have been used as immunosuppressive agents.
39 of renal function if treated with additional immunosuppressive agents.
40 e exposed to higher portal concentrations of immunosuppressive agents.
41 the safety profile of vismodegib with other immunosuppressive agents.
42 ifficult to control with currently available immunosuppressive agents.
43 managed with oral corticosteroids and other immunosuppressive agents.
44 es reproducibly induced or inhibited by both immunosuppressive agents.
45 MHC mismatch without the long-term need for immunosuppressive agents.
46 rally modest efficacy, and can interact with immunosuppressive agents.
47 ertensive medications and the institution of immunosuppressive agents.
48 TLs retain their function in the presence of immunosuppressive agents.
49 tiglaucoma medications, and chemotherapeutic/immunosuppressive agents.
50 nologic rejection, despite the use of potent immunosuppressive agents.
51 e interval [CI], 89.7%-95.9%) were receiving immunosuppressive agents.
52 effectiveness of the drug and possible newer immunosuppressive agents.
53 erved for NMSC and NHL in those treated with immunosuppressive agents.
54 tructural regions of HLA molecules are novel immunosuppressive agents.
55 ed in vitro in the presence of corresponding immunosuppressive agents.
56 ty than that which is seen with conventional immunosuppressive agents.
57 ctivation and allow the development of novel immunosuppressive agents.
58 which need to be recognized and managed with immunosuppressive agents.
59 ibody+ sera (in vitro ADCC), with or without immunosuppressive agents.
60 ing systemic corticosteroids and second-line immunosuppressive agents.
61 spitalization, she was treated with multiple immunosuppressive agents.
62 tapering steroids and/or adding nonbiologic immunosuppressive agents.
63 tumor growth and are influenced by different immunosuppressive agents.
64 l donor HLA matching and use of prophylactic immunosuppressive agents.
65 novel biomarkers and therapeutic targets for immunosuppressive agents.
66 g allospecific regulatory effects of diverse immunosuppressive agents.
67 cells under stress following treatment with immunosuppressive agents.
68 s (DSA-PCs) appear resistant to conventional immunosuppressive agents.
73 ineurin inhibitors (CNIs) are the first-line immunosuppressive agents administered after liver transp
74 without ESRD and without need for additional immunosuppressive agents after TLI was 19% (4 of 21).
79 potent synergistic interactions between the immunosuppressive agents and antifungal drugs against ma
80 have been developed as antiinflammatory and immunosuppressive agents and are currently undergoing te
81 as been attributed to a novel combination of immunosuppressive agents and avoidance of steroids; howe
82 ncreasingly important with widespread use of immunosuppressive agents and broad-spectrum antibiotics.
83 standard dose glucocorticoids and additional immunosuppressive agents and conversely steroid-sparing
84 Immunosuppression involves the nature of the immunosuppressive agents and individual differences in p
87 t physicians, given the increasing number of immunosuppressive agents and the balance between rejecti
88 radox between the antifungal activity of the immunosuppressive agents and the occurrence of fungal in
89 the data available on the risk of individual immunosuppressive agents and their ability to prevent dn
91 s had been treated with at least 3 different immunosuppressive agents, and 5 patients had previously
92 gs are widely used as antileukemic drugs and immunosuppressive agents, and 6-thioguanosine triphospha
94 erapy consists of high-dose corticosteroids, immunosuppressive agents, and intravenous immune globuli
95 eated recipients with CD154 mAb plus various immunosuppressive agents, and performed flow cytometric
99 rgan transplant recipients receiving chronic immunosuppressive agents are at increased risk to acquir
102 ase series provides compelling evidence that immunosuppressive agents are effective at providing long
103 responses such as with anti-inflammatory or immunosuppressive agents are either ineffective, as the
106 condary infection who are being treated with immunosuppressive agents are most at risk for poor outco
109 e, which are well-established anticancer and immunosuppressive agents, are extensively metabolized by
111 een highly active antiretroviral therapy and immunosuppressive agents as well as the potential for hi
113 or later were analyzed to determine whether immunosuppressive agents at the time of first transplant
114 teroids or therapy with corticosteroids plus immunosuppressive agents (azathioprine, cyclophosphamide
116 hibitors are imperfect long-term maintenance immunosuppressive agents because of frequent and irrever
119 red an entity nonresponsive to prednisone or immunosuppressive agents, but it has become apparent ove
120 phritis seems to be a reduction or change of immunosuppressive agents, but this may increase the inhe
121 cocorticoids are potent antiinflammatory and immunosuppressive agents by virtue of their repression o
122 with corticosteroids and other antirheumatic/immunosuppressive agents can preserve hearing and vestib
124 sulfan, cyclophosphamide, or fludarabine and immunosuppressive agents CTLA4-Ig + anti-CD40L or anti-(
127 ited by treatment of infected cells with the immunosuppressive agent cyclosporin A (CsA), HIV-1 infec
134 peutic modulation of psoriasis with targeted immunosuppressive agents defines inflammatory genes asso
136 As LPL may be a target of the commonly used immunosuppressive agent dexamethasone, full elucidation
137 he one transplant recipient not treated with immunosuppressive agents died with anemia and acute vire
139 These findings demonstrate that specific immunosuppressive agents differentially alter the cutane
141 rednisone (</=10 mg/day), antimalarials, and immunosuppressive agents; dosages were required to be st
142 nd the use of more focused and less globally immunosuppressive agents during established rejections m
143 ich target human T cells, are widely used as immunosuppressive agents during treatment of kidney allo
146 and pyrimidine synthesis, is an experimental immunosuppressive agent effective in the prevention/cont
148 ed cancer risk is associated with the use of immunosuppressive agents, especially calcineurin inhibit
150 (PG490), a diterpene triepoxide, is a potent immunosuppressive agent extracted from the Chinese herb
151 ry experiments reveal that the commonly used immunosuppressive agent FK-506 can inhibit TRPC6 activit
153 city of ethonafide might make it a promising immunosuppressive agent for clinical use in treating MS
154 at ILT3-Fc acts through BCL6 and is a potent immunosuppressive agent for reversing the onset of allo-
157 sphamide has been proposed as an alternative immunosuppressive agent for treatment of severe aplastic
158 rat islets to various concentrations of five immunosuppressive agents for 48 and 24 hr, respectively,
162 ipients who had previously been treated with immunosuppressive agents for primary renal disease.
164 ce suggests the therapeutic potential of the immunosuppressive agent FTY720 (fingolimod) in hepatocel
166 hosphamide was ineffective, but noncytotoxic immunosuppressive agents generally produced a good respo
167 ng MTX monotherapy, those receiving biologic immunosuppressive agents had neither an increased nor de
168 mmune disease requiring systemic steroids or immunosuppressive agents, had no active non-infectious p
174 the treatment of choice for IgG4-RHP because immunosuppressive agents have shown variable efficacy in
175 (TAC) and sirolimus (SRL), two commonly used immunosuppressive agents, have demonstrated contrasting
177 phenolate mofetil (MMF) has become a popular immunosuppressive agent in pediatric renal transplantati
178 izumab), which has proven to be a successful immunosuppressive agent in solid organ and bone marrow t
179 proliferation and is well established as an immunosuppressive agent in solid organ transplantation.
180 Anti-CD3 immunotoxins are broad-spectrum immunosuppressive agents in a wide range of organ transp
181 rom treatment with corticosteroids and other immunosuppressive agents in addition to plasma exchange
183 ons also associated with lack of response to immunosuppressive agents in children with steroid-resist
184 morrhagic Retinal Vasculitis with aggressive immunosuppressive agents in collaboration with rheumatol
185 apse; or requirements for steroids and other immunosuppressive agents in Crohn disease or ulcerative
187 fficacious addition to therapy with standard immunosuppressive agents in patients with refractory chi
189 led trials have failed to support the use of immunosuppressive agents in pediatric IgA nephropathy an
190 ients with uveitis, use of noncorticosteroid immunosuppressive agents in selected patients with uveit
191 limus (FK506) is one of the most widely used immunosuppressive agents in SOT recipients, and its immu
192 he large increase in the number of available immunosuppressive agents in the past few years mandates
193 gh concurrent administration of conventional immunosuppressive agents including steroids and calcineu
194 ted over the course of 2 years with numerous immunosuppressive agents, including tumor necrosis facto
196 in the development of PVN, judicious use of immunosuppressive agents is indicated to minimize the oc
199 ical characteristics, drug used (second-line immunosuppressive agent [ISA] or biologicals), and drug
200 teroid treatment have shown good response to immunosuppressive agents known to be effective for artic
202 were closely monitored for trough levels of immunosuppressive agents, laboratory values, and potenti
203 nesis, as shown by successful treatment with immunosuppressive agents, leading to transfusion indepen
204 reviously demonstrated that the experimental immunosuppressive agent leflunomide inhibits production
205 ression of innate and adaptive immunities by immunosuppressive agents limits immunological defense, i
206 s indicate that, in contrast to the standard immunosuppressive agents, macrolides such as RAD may be
209 ulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanc
210 s, decrease and/or discontinuation of potent immunosuppressive agents may contribute to decrease morb
211 oids may further increase damage, but use of immunosuppressive agents may protect against disease dam
213 rolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft
214 sphate (MZP) is the active metabolite of the immunosuppressive agent mizoribine and a potent inhibito
215 Here, we demonstrate that, in the absence of immunosuppressive agents, monotherapy with clinical-grad
217 ding NTZ duration >/=2 years (n = 13), prior immunosuppressive agents (n = 8), and reported anti-JC v
218 e has produced an ideal antiinflammatory and immunosuppressive agent, namely glucocorticoids, and it
219 nocompromised hosts, with discontinuation of immunosuppressive agents necessary to prevent morbidity.
220 The renal function and degree of exposure to immunosuppressive agents of patients shedding polyomavir
221 xtensive systemic illness and treatment with immunosuppressive agents often require patients with rhe
222 orticosteroids, antiplatelet drugs and other immunosuppressive agents often used in combination with
224 ically must take into account the effects of immunosuppressive agents on CD154 induction, which seems
225 id organ allografts; however, the effects of immunosuppressive agents on NK cells are not clearly est
229 e might be used alone or in combination with immunosuppressive agents, or as salvage therapy for pati
230 but many patients do not tolerate first-line immunosuppressive agents, or experience ongoing relapses
232 one of the study participants were receiving immunosuppressive agents other than low-dose steroids an
234 e adhesion could be used in conjunction with immunosuppressive agents, potentially leading to safer a
235 roquine (HCQ), a lysosomotropic amine, is an immunosuppressive agent presently being evaluated in bon
237 hic data; transplant date, type, and source; immunosuppressive agents received at diagnosis; and type
238 roid pulse therapy followed by PSL 45 mg and immunosuppressive agent resulted in a resolution of his
239 ts were treated with immunomodulators and/or immunosuppressive agents, resulting in temporary remissi
241 derivatives may have potential utility as an immunosuppressive agent(s) in modulation of AR and manag
244 ctive of TF, including previous transplants, immunosuppressive agent selection, and almost all recipi
245 monotherapy as the reference group, biologic immunosuppressive agents showed neither protective nor d
248 l, followed by lower dose prednisone plus an immunosuppressive agent such as azathioprine or methotre
250 ; thus, the incorporation of non-nephrotoxic immunosuppressive agents, such as sirolimus, may provide
251 Relatively limited experience with other immunosuppressive agents, such as tacrolimus, has been r
252 y in conjunction with the most commonly used immunosuppressive agents tacrolimus and mycophenolate, a
255 neurin inhibition, ISATX247 is a more potent immunosuppressive agent than cyclosporine in this nonhum
256 Radiation is generally considered to be an immunosuppressive agent that acts by killing radiosensit
257 gs suggest that Dp44mT may serve as a potent immunosuppressive agent that could complicate its use as
261 Human herpesvirus 6 (HHV-6) is a potentially immunosuppressive agent that has been suggested to act a
262 ethyl]-1,3-propanediol hydrochloride) is an immunosuppressive agent that inhibits allograft rejectio
264 CR signaling, has long been recognized as an immunosuppressive agent that inhibits T cell receptor ac
266 nalog DCB-3503 is a potential anticancer and immunosuppressive agent that suppresses the translation
267 duals currently requires potent, nonspecific immunosuppressive agents that are neither completely suc
269 Solid organ transplant recipients receive immunosuppressive agents that make them more susceptible
270 e anti-non gal antibody barrier will require immunosuppressive agents that preferentially inhibit thi
271 erance is giving rise to a new generation of immunosuppressive agents, that can exploit these mechani
272 on of a soluble Gal glycoconjugate and other immunosuppressive agents, the survival of pig hearts in
273 dly important class of anti-inflammatory and immunosuppressive agents, their actions in dendritic cel
275 ipient age, donor age, Child-Pugh class, and immunosuppressive agent to be associated with acute reje
276 Patients requiring a second-line systemic immunosuppressive agent to control their PSII were treat
278 on is incomplete or while they are receiving immunosuppressive agents to prevent or treat graft-versu
279 on to the concomitant and alternative use of immunosuppressive agents to steroid therapy, disease rem
280 mits is recommended, and the contribution of immunosuppressive agents to the development of PTDM is a
281 ted against human T lymphocytes, is a potent immunosuppressive agent used to reverse and more recentl
285 as use of oral glucocorticoids and cytotoxic immunosuppressive agents was associated with significant
286 e inhibitors of IMPDH are in clinical use as immunosuppressive agents, we have examined the consequen
287 temic corticosteroid and >/=1 other systemic immunosuppressive agent were enrolled from January 2007
288 ystemic corticosteroids and at least 1 other immunosuppressive agent were enrolled from January 2007
289 long-term safety for this approach, when the immunosuppressive agents were antimetabolites or calcine
293 th active SLE that was resistant to standard immunosuppressive agents were treated with B cell deplet
296 of patients without alterations responded to immunosuppressive agents), whereas clinical features, ag
297 tanding of the interactions between Treg and immunosuppressive agents will be valuable to the effecti
299 porphyrin, and butylated hydroxytoluene), an immunosuppressive agent with antivascular endothelial gr
300 ceeding to Tier 2, which comprises a host of immunosuppressive agents with relatively lower response
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。